Mayr William T, Rodriguez Moses
Department of Neurology, Mayo Clinic Rochester, USA.
Minn Med. 2002 Jun;85(6):36-9.
Multiple sclerosis (MS) is the most common cause of neurological disability in young European and North American adults. It is defined as dysfunction in different parts of the central nervous system at different points in time. The etiology is likely autoimmune, resulting from environmental and genetic factors. This article summarizes the symptoms, progression, diagnosis, and treatment of MS. MRI and CSF studies have been extremely helpful in identifying individual cases, but the diagnosis remains a clinical diagnosis, and one of exclusion. Methylprednisolone remains the preferred treatment for acute relapses, although plasma exchange has been shown to be helpful in cases when methylprednisolone has failed. Preventive immunomodulatory treatments are the focus of many current research efforts. Although these treatments have been shown to reduce the frequency of MS attacks, the reduction is modest, at 30%. The data that these drugs alter the progression of disability is less compelling.
多发性硬化症(MS)是欧洲和北美年轻成年人神经功能障碍最常见的病因。它被定义为中枢神经系统不同部位在不同时间点出现的功能障碍。其病因可能是自身免疫性的,由环境和遗传因素导致。本文总结了多发性硬化症的症状、病程、诊断和治疗。磁共振成像(MRI)和脑脊液研究在识别个别病例方面非常有帮助,但诊断仍然是临床诊断,且是排除性诊断之一。甲基强的松龙仍然是急性复发的首选治疗药物,尽管血浆置换已被证明在甲基强的松龙治疗失败的情况下有帮助。预防性免疫调节治疗是当前许多研究工作的重点。尽管这些治疗已被证明可降低多发性硬化症发作的频率,但降低幅度不大,为30%。这些药物能改变残疾进展的数据说服力较弱。